A clinical feasible stem cell encapsulation ensures an improved wound healing.
ADSCs
biosynsphere
encapsulation
tissue regeneration
wound healing
Journal
Biomedical materials (Bristol, England)
ISSN: 1748-605X
Titre abrégé: Biomed Mater
Pays: England
ID NLM: 101285195
Informations de publication
Date de publication:
06 02 2023
06 02 2023
Historique:
received:
21
10
2022
accepted:
26
01
2023
pubmed:
27
1
2023
medline:
8
2
2023
entrez:
26
1
2023
Statut:
epublish
Résumé
Cell encapsulation has proven to be promising in stem cell therapy. However, there are issues needed to be addressed, including unsatisfied yield, unmet clinically friendly formulation, and unacceptable viability of stem cells after cryopreservation and thawing. We developed a novel biosynsphere technology to encapsulate stem cells in clinically-ready biomaterials with controlled microsphere size. We demonstrated that biosynspheres ensure the bioviability and functionality of adipose-derived stromal cells (ADSCs) encapsulated, as delineated by a series of testing procedures. We further demonstrated that biosynspheres protect ADSCs from the hardness of clinically handling such as cryopreservation, thawing, high-speed centrifugation and syringe/nozzle injection. In a swine full skin defect model, we showed that biosynspheres were integrated to the destined tissues and promoted the repair of injured tissues with an accelerating healing process, less scar tissue formation and normalized deposition of collagen type I and type III, the ratio similar to that found in normal skin. These findings underscore the potential of biosynsphere as an improved biofabrication technology for tissue regeneration in clinical setting.
Identifiants
pubmed: 36701809
doi: 10.1088/1748-605X/acb67a
doi:
Substances chimiques
Collagen Type I
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Creative Commons Attribution license.